About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

NCT02026401·17 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

NGM Biopharmaceuticals, Inc

With

NGM Biopharmaceuticals Australia Pty Ltd

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Males or females, between 18 and 75 years of age, inclusive
PBC diagnosis consistent with AASLD and EASL guidelines
Stable dose of UDCA

You may not be if

Chronic liver disease of a non-PBC etiology
Evidence of clinically significant hepatic decompensation

The record

StatusCompleted

PhasePhase 2

Taking part45

StartedFeb 2014

UpdatedMar 28, 2017

Conditions

Primary Biliary Cirrhosis

Where17

NGM Clinical Study Site 103
Phoenix, Arizona, United States
NGM Clinical Study Site 108
Coronado, California, United States
NGM Clinical Study Site 101
Detroit, Michigan, United States

Clareo Health | Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis